148 related articles for article (PubMed ID: 35962301)
1. HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer.
Esfahani SA; de Aguiar Ferreira C; Rotile NJ; Ataeinia B; Krishna S; Catalano OA; Caravan P; Yen YF; Heidari P; Mahmood U
Mol Imaging Biol; 2023 Apr; 25(2):353-362. PubMed ID: 35962301
[TBL] [Abstract][Full Text] [Related]
2. Hyperpolarized [1-
Esfahani SA; Callahan C; Rotile NJ; Heidari P; Mahmood U; Caravan PD; Grant AK; Yen YF
Mol Imaging Biol; 2022 Oct; 24(5):769-779. PubMed ID: 35467249
[TBL] [Abstract][Full Text] [Related]
3. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
Janjigian YY; Viola-Villegas N; Holland JP; Divilov V; Carlin SD; Gomes-DaGama EM; Chiosis G; Carbonetti G; de Stanchina E; Lewis JS
J Nucl Med; 2013 Jun; 54(6):936-43. PubMed ID: 23578997
[TBL] [Abstract][Full Text] [Related]
4.
Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
[TBL] [Abstract][Full Text] [Related]
5. Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide.
Larimer BM; Phelan N; Wehrenberg-Klee E; Mahmood U
Mol Imaging Biol; 2018 Apr; 20(2):300-308. PubMed ID: 28733706
[TBL] [Abstract][Full Text] [Related]
6. HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
Wehrenberg-Klee E; Sinevici N; Nesti S; Kalomeris T; Austin E; Larimer B; Mahmood U
Mol Imaging Biol; 2021 Dec; 23(6):930-940. PubMed ID: 34101105
[TBL] [Abstract][Full Text] [Related]
7. Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.
Keller S; Zwingenberger G; Ebert K; Hasenauer J; Wasmuth J; Maier D; Haffner I; Schierle K; Weirich G; Luber B
Mol Oncol; 2018 Apr; 12(4):441-462. PubMed ID: 29325228
[TBL] [Abstract][Full Text] [Related]
8. Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer.
Zhang C; Awasthi N; Schwarz MA; Schwarz RE
J Surg Res; 2013 Jun; 182(2):227-34. PubMed ID: 23201270
[TBL] [Abstract][Full Text] [Related]
9. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.
Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
[TBL] [Abstract][Full Text] [Related]
10. Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance.
Wehrenberg-Klee E; Turker NS; Heidari P; Larimer B; Juric D; Baselga J; Scaltriti M; Mahmood U
J Nucl Med; 2016 Sep; 57(9):1413-9. PubMed ID: 27081168
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
Yoshioka T; Shien K; Takeda T; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Soh J; Fujiwara T; Toyooka S
Cancer Sci; 2019 Aug; 110(8):2549-2557. PubMed ID: 31162771
[TBL] [Abstract][Full Text] [Related]
12. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
13. Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
Rinne SS; Dahlsson Leitao C; Saleh-Nihad Z; Mitran B; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183096
[TBL] [Abstract][Full Text] [Related]
14. Affibody-mediated PET imaging of HER3 expression in malignant tumours.
Rosestedt M; Andersson KG; Mitran B; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Sci Rep; 2015 Oct; 5():15226. PubMed ID: 26477646
[TBL] [Abstract][Full Text] [Related]
15. Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
Ebert K; Zwingenberger G; Barbaria E; Keller S; Heck C; Arnold R; Hollerieth V; Mattes J; Geffers R; Raimúndez E; Hasenauer J; Luber B
BMC Cancer; 2020 Oct; 20(1):1039. PubMed ID: 33115415
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
[TBL] [Abstract][Full Text] [Related]
17. Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors.
Pereira PMR; Mandleywala K; Ragupathi A; Carter LM; Goos JACM; Janjigian YY; Lewis JS
J Nucl Med; 2019 Nov; 60(11):1569-1578. PubMed ID: 31171598
[TBL] [Abstract][Full Text] [Related]
18. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
[TBL] [Abstract][Full Text] [Related]
19. Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF.
Ebert K; Haffner I; Zwingenberger G; Keller S; Raimúndez E; Geffers R; Wirtz R; Barbaria E; Hollerieth V; Arnold R; Walch A; Hasenauer J; Maier D; Lordick F; Luber B
BMC Cancer; 2022 Mar; 22(1):254. PubMed ID: 35264144
[TBL] [Abstract][Full Text] [Related]
20. Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of
Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30832342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
